The Glycolytic System: What It Is and How It Works

The glycolytic system is the metabolic pathway that breaks glucose down into a smaller molecule called pyruvate, generating usable energy along the way. It consists of ten enzyme-driven chemical reactions that occur in the fluid portion of virtually every cell, and it is so fundamental that it operates in nearly all living organisms on Earth.¹ Whether you are sprinting across a parking lot or sitting still reading this sentence, glycolysis is running in your cells right now, feeding the rest of your metabolism its starting materials.

The Two Phases of Glycolysis

Glycolysis unfolds in two halves, and understanding the split helps the rest of the pathway make sense. The first half is an energy-investment phase. Your cell actually spends two molecules of ATP, its main energy currency, to get glucose into the right chemical shape for splitting. First, an enzyme called hexokinase tacks a phosphate group onto glucose, locking it inside the cell. A few reactions later, another enzyme called phosphofructokinase adds a second phosphate. The result is a six-carbon sugar loaded with phosphate groups, which then gets cleaved in half into two three-carbon molecules.²

The second half is the payoff phase. Each of those two three-carbon molecules goes through a series of reactions that strip off electrons (captured by a carrier molecule called NAD+, which becomes NADH) and transfer phosphate groups directly onto ADP to make ATP. Because each half of the original glucose runs through the payoff phase independently, the cell gets four ATP molecules out. Subtract the two it invested at the start, and the net gain is two ATP per glucose. That sounds modest, and it is, but the speed at which glycolysis runs is what makes it valuable. During intense physical effort, your muscles can ramp ATP demand to roughly a thousand times the resting rate, and glycolysis is one of the first systems to respond.³

What Happens After Pyruvate

Glycolysis itself ends with pyruvate. What your cell does with that pyruvate depends almost entirely on whether enough oxygen is available. When oxygen is plentiful, pyruvate enters the mitochondria, the organelles often called the cell’s power plants, and feeds into a much longer series of reactions (the citric acid cycle, then the electron transport chain) that extracts far more energy. A single glucose molecule processed fully through those aerobic pathways can yield around 30 to 36 ATP, dwarfing the two from glycolysis alone.

When oxygen is scarce or energy demand outstrips its supply, the cell takes a shortcut. An enzyme called lactate dehydrogenase (LDH) converts pyruvate into lactate. This reaction matters less for the lactate itself and more for a chemical housekeeping reason: it regenerates NAD+. Glycolysis burns through NAD+ during the payoff phase, and without a fresh supply the whole pathway grinds to a halt. Converting pyruvate to lactate recycles NAD+ so glycolysis can keep turning.⁴ That recycling step is exactly why you can produce energy anaerobically, without oxygen, even though it is far less efficient.

Lactate, though, is not a dead end. Your liver can pick it up from the bloodstream and convert it back into glucose through a process called gluconeogenesis, essentially running glycolysis in reverse using different enzymes. The glucose is then shipped back out to muscles and other tissues that need it. This loop between muscle-produced lactate and liver-produced glucose is called the Cori cycle, and it acts as a carbon-recycling system between organs.⁵ During prolonged exercise, this interorgan cross talk becomes essential for maintaining blood glucose levels.⁶

How the Pathway Is Regulated

Your cells do not run glycolysis at a fixed rate. They speed it up or slow it down depending on how much energy they need, and the master switch for this control sits at the enzyme phosphofructokinase-1 (PFK-1), the one that catalyzes the second ATP-spending step in the investment phase. PFK-1 is considered the main regulatory checkpoint of the entire pathway because its reaction is essentially irreversible under normal cellular conditions, making it a bottleneck the cell can tighten or loosen.

PFK-1 is exquisitely sensitive to the cell’s energy status. When ATP levels are high, meaning the cell has plenty of energy, ATP itself binds to an inhibitory site on PFK-1 and slows the enzyme down. When ATP drops and its breakdown products ADP and AMP accumulate, those molecules bind at an activating allosteric site on PFK-1, which flips the enzyme into a more active shape.⁷ The logic is elegant: low energy triggers more glycolysis, high energy slows it. PFK-1 also responds to signals from other metabolic pathways and hormones like insulin, which helps coordinate glycolysis with the body’s broader nutritional state.

The other two irreversible enzymes, hexokinase at the entry and pyruvate kinase at the exit, also serve as regulation points, though PFK-1 gets the most attention because of how many different signals converge on it. Together, these three checkpoints let the cell fine-tune glucose breakdown with impressive precision.

Glycolysis and Exercise

If you have ever felt that burning sensation during an all-out sprint or the last few reps of a heavy lift, you have felt glycolysis working overtime. Your body uses three overlapping energy systems to regenerate ATP during physical activity: the phosphagen system (which relies on stored creatine phosphate and runs out in seconds), the glycolytic system, and mitochondrial respiration (the aerobic engine). All three contribute simultaneously, but the proportional contribution of each shifts depending on how hard and how long you are working.³

During short, intense bursts lasting roughly ten seconds to two minutes, glycolysis is the dominant ATP supplier. It can regenerate ATP at a high rate, but the total amount of energy it can deliver in a single bout is limited.⁸ That is partly because the accumulation of lactate and hydrogen ions lowers the pH inside the muscle cell, which eventually inhibits the very glycolytic enzymes that are producing the energy. This is one reason you cannot maintain an all-out sprint forever. For efforts lasting longer than a couple of minutes, the aerobic system gradually takes over as the primary contributor, though glycolysis never shuts off completely.

Coaches and exercise scientists sometimes describe training programs as targeting the “glycolytic system” specifically. Interval training with work bouts of 30 seconds to two minutes, followed by rest periods, is a classic approach to stressing this pathway. The practical goal is to improve the muscles’ capacity to tolerate the metabolic byproducts of fast glycolysis, effectively pushing back the point at which fatigue forces you to slow down.

How Different Tissues Rely on Glycolysis

Not every tissue in your body uses glycolysis the same way. Your brain, which accounts for roughly a fifth of your resting energy expenditure, runs primarily on glucose and was long thought to rely almost entirely on aerobic metabolism. But research over the past few decades has revealed a more collaborative arrangement. Astrocytes, the support cells surrounding neurons, take up glucose, run it through glycolysis, and release the resulting lactate. Neighboring neurons then import that lactate and burn it in their mitochondria for energy. This concept is known as the astrocyte-neuron lactate shuttle.⁹ The trigger for the astrocytes to ramp up glycolysis is neuronal activity itself. When a neuron fires, it releases a signaling molecule called glutamate, which astrocytes absorb. That uptake process increases the astrocyte’s energy demand, driving more glucose uptake and glycolysis, and the resulting lactate flows back out to fuel the neurons that started the whole process.¹⁰

Red blood cells represent the most extreme case. They have no mitochondria at all, so glycolysis is their only source of ATP. Every bit of energy a red blood cell needs to maintain its membrane, power its ion pumps, and keep its shape comes from fermentation of glucose to lactate. Red blood cells also produce a unique glycolytic side product called 2,3-diphosphoglycerate (2,3-DPG), which branches off from one of the intermediate steps. 2,3-DPG binds to hemoglobin and reduces its grip on oxygen, making hemoglobin more willing to release oxygen into tissues that need it. When 2,3-DPG levels rise, as happens at high altitude or during anemia, the oxygen-release curve shifts and tissues get more oxygen per pass of blood.¹¹ It is a fascinating case where a glycolytic intermediate does double duty, serving not just metabolism but oxygen transport.

Cancer and the Warburg Effect

In the 1920s, the German biochemist Otto Warburg noticed something strange about cancer cells: even when plenty of oxygen was available, they consumed far more glucose than normal cells and converted most of it to lactate rather than feeding it into the mitochondria. This metabolic quirk, now called the Warburg effect, is one of the most consistent features of cancer biology.¹² The puzzle is why a cancer cell would choose the less efficient route. Aerobic glycolysis produces only two ATP per glucose, while full mitochondrial oxidation produces many times more.

The leading explanation is that for a cell whose main job is to grow and divide, raw ATP is not the bottleneck. Building a new cell requires nucleotides, amino acids, and lipids, and the intermediates of glycolysis serve as starting materials for all of these biosynthetic pathways. By running glycolysis at a high rate and diverting intermediates into building blocks rather than burning everything to carbon dioxide, cancer cells get the materials they need to replicate.¹³ Fructose metabolism can further enhance this metabolic adaptability in cancer cells, feeding into many of the same biosynthetic pipelines, especially when glucose is in short supply.¹⁴

This heavy glucose appetite has a practical clinical application. PET scans used to detect cancer work by injecting a radioactive glucose analog called FDG (fluorodeoxyglucose). Cancer cells gobble it up at a much higher rate than surrounding normal tissue, lighting up on the scan. FDG-PET imaging has transformed how cancers are diagnosed and how doctors track whether a treatment is working.¹⁵ In a sense, the Warburg effect is a vulnerability. The very thing that helps cancer cells grow also makes them visible.

When Glycolytic Enzymes Break

Because glycolysis is so central to cell function, inherited mutations in its enzymes tend to cause serious disease. One well-studied example is pyruvate kinase deficiency, caused by mutations in the PKLR gene. Pyruvate kinase catalyzes the last step of glycolysis, the one that generates the final ATP. When it malfunctions, red blood cells suffer most because, as described above, they depend entirely on glycolysis for energy. The result is chronic hemolytic anemia: red blood cells break apart faster than the body can replace them, leading to fatigue, jaundice, and in severe cases organ complications.¹⁶

Another example is phosphofructokinase deficiency (Tarui disease, or glycogen storage disease type VII), caused by mutations in the PFKM gene, which encodes the muscle form of PFK. Because PFK catalyzes the main regulatory step of glycolysis, losing its activity blocks glycolysis in muscle. Patients experience severe exercise intolerance and muscle weakness. Research in mice lacking PFKM has shown that the disease is more systemic than originally appreciated. Even though these mice retained half the normal PFK activity in their red blood cells, they still developed hemolysis, reduced 2,3-DPG levels, cardiac hypertrophy, and impaired oxygen delivery to tissues.¹⁷ The reduced 2,3-DPG is a direct consequence of glycolysis being blocked upstream: if you cannot make the intermediate that 2,3-DPG branches off from, you cannot make 2,3-DPG. The result is that hemoglobin holds onto oxygen too tightly, starving muscles even further.

Glycolytic Enzymes Have Side Jobs

One of the more surprising findings in recent cell biology is that several glycolytic enzymes do far more than process sugar. Researchers have found that these supposedly “housekeeping” proteins moonlight in roles that include controlling cell division, regulating gene expression, influencing whether a cell lives or dies, and even guiding cell migration.¹⁸ Hexokinase, for instance, can bind to the outer membrane of mitochondria and suppress apoptosis, the process of programmed cell death. In cancer, this moonlighting behavior can become co-opted: by blocking apoptosis, hexokinase helps tumor cells survive when they otherwise should not.

These discoveries have muddied the once-clean picture of glycolysis as a simple metabolic assembly line. The enzymes are not just catalysts sitting passively in the cytoplasm waiting for their substrate to arrive. They shuttle between compartments, interact with DNA-binding proteins, and respond to signals that have nothing obvious to do with glucose breakdown. This dual nature makes glycolytic enzymes attractive drug targets in cancer and other diseases, but it also means that interfering with one enzyme’s metabolic role may inadvertently disrupt its non-metabolic functions, or vice versa.

Glycolysis in Other Organisms

Glycolysis is often presented as a universal pathway, but the details vary in fascinating ways across the tree of life. One of the most striking variations occurs in trypanosomes, the single-celled parasites responsible for diseases like African sleeping sickness. In most cells, glycolysis takes place freely in the cytoplasm. In trypanosomes and their relatives, the first seven steps of glycolysis are walled off inside a specialized compartment called a glycosome.¹⁹

Why bother? Computer modeling of the trypanosome’s biochemistry revealed that the compartment does not speed up glycolysis, as researchers originally speculated. Instead, it prevents a dangerous buildup of sugar phosphates, the intermediates from the investment phase. If those intermediates accumulate uncontrollably in the cytoplasm, the cell is in trouble. The glycosome membrane acts as a safety barrier, containing the “turbo” design of the early glycolytic steps where ATP is consumed before any is recovered.²⁰ Because trypanosomes depend so heavily on glycolysis for energy (they have reduced mitochondrial function in the mammalian bloodstream stage of their life cycle), any disruption of their glycosomes is lethal, which makes the compartment an attractive target for antiparasitic drugs.

How Glycolysis Evolved

Given that glycolysis breaks down glucose, you might assume it evolved because early organisms had glucose lying around to eat. The evidence suggests the opposite. Researchers have proposed that the reactions of glycolysis originally ran in reverse, as part of gluconeogenesis, the pathway that builds glucose from simpler carbon compounds. The earliest cells were likely autotrophs that used hydrogen gas and carbon dioxide to synthesize their own carbon building blocks. They needed to make molecules like pyruvate and three-carbon sugar phosphates for amino acid and cofactor synthesis, and the enzymatic steps that accomplish this overlap heavily with glycolysis run backward.²¹

The idea is that once cells evolved the ability to build and store glycogen, an internal glucose reserve, they then needed enzymes to break that glycogen back down for energy. The sugar-degrading direction of glycolysis was repurposed from the biosynthetic pathway that already existed. This would explain a puzzle in microbiology: glycogen synthesis and gluconeogenesis are found in nearly all prokaryotes, but glycolysis in the glucose-to-pyruvate direction is not universal.²¹ The building direction came first; the breaking direction came later. The pathway’s name, “glycolysis” (literally “sugar splitting”), describes what we observe it doing in modern organisms, but the enzymes likely originated to do the opposite. The discovery of the Embden-Meyerhof-Parnas pathway, as glycolysis is formally known, was itself a milestone that helped launch modern biochemistry, yet the evolutionary story behind it keeps getting richer.²²